JAZZ:NASDAQ
재즈파마슈티컬즈
US$231.39
arrow_downward
-1.97%(-4.65) 1D
US$232.45
arrow_upward
+0.46% (+1.06)today개장 전 거래
휴장: 10월 6일, 오후 4시 0분 1초 GMT-4 · USD
search
모든 종목 코드
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoJAZZ의 주요 통계 생성 중...
시가
US$236.40
고가
US$236.40
저가
US$228.70
시가총액
149.97억
평균 거래량
99.03만
거래량
1.13천
주가수익률
15.82
52주 최고가
US$266.38
52주 최저가
US$128.80
EPS
US$14.63
베타
0.37
유통 주식수
6491.50만
직원 수
3천
시가
US$236.40
고가
US$236.40
저가
US$228.70
시가총액
149.97억
평균 거래량
99.03만
거래량
1.13천
주가수익률
15.82
52주 최고가
US$266.38
52주 최저가
US$128.80
EPS
US$14.63
베타
0.37
유통 주식수
6491.50만
직원 수
3천
뉴스 기사
웹 소스 및 뉴스 파트너 제공
프로필
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
재즈파마슈티컬즈에 관한 정보